Compare AU
Compare QSML vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the MSCI World Small Cap Quality 150 (ex AUS) (QSML) and the BetaShares Global Healthcare ETF - Currency Hedged (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
QSML | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 89 | 63 |
Median incremental investment | $1,000.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,985.76 | $1,921.92 |
Average age group | > 35 | 26 - 35 |
Key Summary
QSML | DRUG | |
|---|---|---|
Strategy | QSML.AX was created on 2021-03-08 by VanEck. The fund's investment portfolio concentrates primarily on small cap equity. The Fund gives investors a diversified portfolio of 150 international developed market small-cap quality growth companies having durable business models and sustainable competitive advantages. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Comfort Systems USA Inc (1.79 %) Toll Brothers Inc (1.44 %) Saia Inc (1.38 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Industrials (51.56 %) Consumer Staples (19.01 %) Financials (18.40 %) | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) |
Top 3 countries | United States (81.64 %) United Kingdom of Great Britain and Northern Ireland (8.09 %) Japan (2.80 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.59 % | 0.57 % |
Key Summary
QSML | DRUG | |
|---|---|---|
Issuer | VanEck | BetaShares |
Tracking index | MSCI World ex Australia Small Cap Quality 150 Index - AUD - Benchmark TR Net | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.59 % | 0.57 % |
Price | $31.85 | $8.25 |
Size | $1.132 billion | $182.401 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.08 % | 1.90 % |
Market | ASX | ASX |
First listed date | 09/03/2021 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
QSML | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 89 | 63 |
Median incremental investment | $1,000.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,985.76 | $1,921.92 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
QSML | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
QSML | DRUG |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |